Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 174M | 205M | 194M | 174M |
| Gross Profit | 127M | 156M | 137M | 115M |
| Operating Income | 67M | 70M | 71M | 20M |
| EBITDA | 70M | 77M | 86M | 30M |
| Net Income | 51M | 47M | 39M | 6M |
| EPS (Diluted) | — | — | — | — |
Industrials
Live Price
Offline$3.07
+2.33% today
1Y Change
-30.88%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SBC Medical Group Holdings Incorporated (SBC) is a Industrials stock with a market cap of $340.00M and listed on NASDAQ. The stock last traded around $3.07 and down 30.9% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -15.5%, EPS growth of +3.6%, a dividend yield of 0.0%. What stands out right now is revenue -15.5%, EPS +3.6%, free cash flow +112.8% with operating margin 38.9% and ROIC 12.6%. Valuation is more restrained than many high-expectation growth names at P/E 6.7 and price/sales 2.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SBC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Industrials peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SBC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SBC Max Drawdown
-49.20%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SBC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$174.2M
-10.0% YoY
FY Net Income
$6.3M
-84.0% YoY
Free Cash Flow
-$25.0M
-163.4% YoY
Revenue Growth
-15.5%
EPS Growth
+3.6%
Gross Margin
72.9%
Net Margin
29.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 174M | 205M | 194M | 174M |
| Gross Profit | 127M | 156M | 137M | 115M |
| Operating Income | 67M | 70M | 71M | 20M |
| EBITDA | 70M | 77M | 86M | 30M |
| Net Income | 51M | 47M | 39M | 6M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & Equivalents | 164M | 125M | 103M | 52M |
| Total Assets | 380M | 266M | 259M | 225M |
| Total Liabilities | 117M | 71M | 115M | 118M |
| Shareholder Equity | 248M | 195M | 142M | 105M |
| Total Debt | 52M | 12M | 23M | 16M |
| Net Debt | -112M | -113M | -80M | -36M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
47K
-100.1% YoY
Capital Expenditures
25M
-122.6% YoY
Free Cash Flow
25M
-163.4% YoY
Key ratios
Gross Margin
72.9%
Operating Margin
38.9%
Net Margin
29.4%
ROE
21.1%
Debt / Equity
0.21x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.